Trial · NCT02192684
Obesity, Sleep Apnea, and Insulin Resistance
NCT02192684, Not applicable, Completed, Stanford University; results first posted 2017-04-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Obesity, Sleep Apnea, and Insulin Resistance. Trials, record NCT02192684. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02192684
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Obesity, Sleep Apnea, and Insulin Resistance
- NCT number
- NCT02192684
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 45 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Insulin Sensitivity, Obstructive Sleep Apnea
- Interventions
- Pioglitazone, placebo
- First posted
- 2014-07-17
- Last updated
- 2017-04-21
- Results first posted
- 2017-04-21
- Limitations and caveats
- Unrecognized adverse effect of pioglitazone could have obviated a beneficial effect of enhanced insulin sensitivity on OSA related sleep measures.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo | 8 weeks | To evaluate the effects of pioglitazone versus placebo on AHI in patients with OSA. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo | 8 weeks | AHI events/hour | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo | Pioglitazone | 35.8 | Inter-Quartile Range 21 to 49 | AHI events/hour | |
| Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo | Placebo | 34.4 | Inter-Quartile Range 18 to 47 | AHI events/hour |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pioglitazone | 30 | |
| Overall Study | STARTED | Placebo | 15 | |
| Overall Study | COMPLETED | Pioglitazone | 30 | |
| Overall Study | COMPLETED | Placebo | 15 | |
| Overall Study | NOT COMPLETED | Pioglitazone | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | weight gain | Product Issues | Pioglitazone | 2 | 30 | 2 |
| other | weight gain | Product Issues | Placebo | 0 | 15 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pioglitazone | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Pioglitazone | 2 | 30 |
| Total, other adverse events | Placebo | 0 | 15 |
| Total, serious adverse events | Pioglitazone | 0 | 30 |
| Total, serious adverse events | Placebo | 0 | 15 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27544837 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL108647 | Sleep apnea, Type 2 diabetes, and CVD: a cluster related to insulin resistance | REAVEN, GERALD M. | STANFORD UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2011 to 2014 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Pioglitazone vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02192684
GET https://conductscience.org/api/trials/v1/NCT02192684/registered